<unk>  is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000,<unk>  was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.<unk>  is given intravenously and drug plasma concentrations reach steady state in 1–3 hours.<unk>  is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).
Argatroban
Rivaroxaban
Apixaban
Hirudin
Bivalirudin
Lusutrombopag
Lepirudin
Tenecteplase